Holland & Knight Advises Investor Syndicate in $135 Million Health Tech Financing

SAN FRANCISCO (September 23, 2021) – Holland & Knight served as lead counsel to an investor syndicate that includes Morgan Stanley Expansion Capital and Ally Bridge Group on the group's $135 million investment in Elligo Health Research®, a healthcare-enabling research organization powered by the novel IntElligo® technology.

The Series E financing also included participation from Norwest Venture Partners and all major existing investors in Elligo, including Cerner, Hatteras Venture Partners, Noro-Moseley Partners, Piper Jaffray Merchant Banking, Shumway Capital and Syneos Health.

Based in Austin, Texas, Elligo combines proprietary data, technology and services to support all trial designs — traditional, hybrid, and direct-to-patient — to expand and accelerate patient access to client trials. Elligo’s solutions address rising challenges faced by all key stakeholders in the clinical trial industry, including top pharma and biotech companies, contract research organizations and research sites.

Holland & Knight Partner Gloria Skigen and Associate Laura Nickerson and led the firm's representation on the deal. They received support from Partners Jennifer Rangel, Shannon Hartsfield, Michael Werner, Elizabeth Burkhard and Victoria Zerjav and Associates Sakinah Jones, Jenna Schapiro, Sahar Shirazi, Alexa Marie Derkasch, H. Harold Lee, Matthew Sloane, Michael Romeo and Sara Klock.